METHOD AND AGENT FOR PREVENTING INTRA- AND POSTOPERATIVE COMPLICATIONS IN PATIENT WITH LUNG CANCER AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

摘要

FIELD: medicine.;SUBSTANCE: method involves a perioperative drug therapy. Spiriva® Respimat® is administered in accordance with the following regimen: at the preoperative stage - in a dose of 2.5 mcg 2 inhalations once a day for 2 weeks; on the day of operation - before general anaesthesia and artificial pulmonary ventilation, in a dose of 2.5 mcg 1 inhalation, and during surgical management 1 inhalation in a dose of 2.5 mcg is used in an operated lung directly through a two-lumen intratracheal tube immediately after ventilation is restored; in the postoperative period - in a dose of 2.5 mcg 2 inhalations once a day for 2 weeks.;EFFECT: optimal clinical course of the perioperative period, more effective treatment by reducing a rate of intra- and postoperative bronchopulmonary complications in the above group of patients.;2 cl, 2 tbl, 1 ex